CHICAGO, IL, UNITED STATES, December 14, 2022 /EINPresswire.com/ — MPN Research Foundation (MPNRF) announces its 2022 Thrive Initiative recipients for projects that fill research funding gaps, some of which surfaced due to the pandemic. This $1.8 million in awards is in addition to currently funded research projects supported for 2021-2023.
MPNRF has invested more than $18.4 million over the past 21 years toward better understanding and treatment of essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), rare blood cancers collectively known as myeloproliferative neoplasms (MPNs).
“The 2022 Thrive Initiative will fund 11 additional MPN research projects totaling $1.8 million over two years,” according to Kapila Viges, MPNRF chief executive officer. “These include an exciting mix of seasoned MPN researchers, awarded for follow-on support to continue their existing projects, in many cases stalled by the pandemic, as well as junior and established investigators with new ideas and perspectives to explore. Together, they bring new talent and energy to solve compelling MPN questions, pioneering the way for new research and treatments.”
“We are thrilled to fund so many new or incomplete projects that otherwise might be left on the research bench without support,” says Brandon Goetzman, MPNRF board member and chair of the Scientific Steering Committee. “Each project went through a rigorous peer review process, with final selections based on scientific merit, independent of research focus.“